In this review:
This publication is a summary of selected presentations delivered at the AbbVie-sponsored ImmuneMediated Inflammatory Diseases (IMID) Promotional Education Meeting, covering sessions across its immunology portfolio: RINVOQ® (upadacitinib); SKYRIZI® (risankizumab); and HUMIRA® (adalimumab).
Please login below to download this issue (PDF)